DrugPatentWatch Database Preview

Sb Pharmco Company Profile

« Back to Dashboard

What is the competitive landscape for SB PHARMCO, and when can generic versions of SB PHARMCO drugs launch?

SB PHARMCO has three approved drugs.

There are two US patents protecting SB PHARMCO drugs.

There are one hundred and ten patent family members on SB PHARMCO drugs in forty-six countries and fifty-six supplementary protection certificates in fourteen countries.

Summary for Sb Pharmco

International Patents:	110
US Patents:	2
Tradenames:	3
Ingredients:	3
NDAs:	3

Drugs and US Patents for Sb Pharmco

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-002	May 25, 1999		RX	Yes	No	7,358,366*PED				Y
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-004	Mar 30, 2007		DISCN	Yes	No	7,358,366*PED				Y
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-003	May 25, 1999		RX	Yes	No	7,358,366*PED				Y
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-004	May 25, 1999		DISCN	Yes	No	7,358,366*PED				Y
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-001	Nov 23, 2005		DISCN	Yes	No	7,358,366*PED				Y

Expired US Patents for Sb Pharmco

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-001	Nov 23, 2005	5,741,803*PED
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-002	Oct 10, 2002	5,741,803*PED
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-002	Oct 10, 2002	7,358,366*PED
Sb Pharmco	AVANDAMET	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	021410-004	Aug 25, 2003	5,002,953*PED
Sb Pharmco	AVANDARYL	glimepiride; rosiglitazone maleate	TABLET;ORAL	021700-005	Mar 30, 2007	7,358,366*PED

Paragraph IV (Patent) Challenges for SB PHARMCO drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	1 mg/ 500 mg, 2 mg/ 500mg, 4 mg/ 500 mg, 2 mg/ 1000 mg and 4 mg/ 1000 mg		2004-10-22
	Tablets	8 mg/2 mg and 8 mg/4 mg		2008-05-30
	Tablets	1 mg/4 mg, 2 mg/4 mg and 4 mg/4 mg		2006-12-22

International Patents for Sb Pharmco Drugs

Country	Patent Number	Estimated Expiration
Denmark	1231918
Morocco	25567
China	1152878
Bulgaria	65517
European Patent Office	1913945

Supplementary Protection Certificates for Sb Pharmco Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	C300357	Netherlands		PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
1412357	PA2008013,C1412357	Lithuania		PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716
1261586	C300524	Netherlands		PRODUCT NAME: COMBINATIE VAN SAXAGLIPTINE EN METFORMINE, DESGEWENST IN DE VORM VAN FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN; NAT. REGISTRATION NO/DATE: EU/1/11/731/001-012 20111124; FIRST REGISTRATION:
1506211	PA2014026	Lithuania		PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
1506211	PA2014026,C1506211	Lithuania		PRODUCT NAME: DAPAGLIFLOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Sb Pharmco